<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02569307</url>
  </required_header>
  <id_info>
    <org_study_id>PILL-NAYAB-001</org_study_id>
    <nct_id>NCT02569307</nct_id>
  </id_info>
  <brief_title>Minocycline and/or Omega-3 Fatty Acids Added to Treatment as Usual for At Risk Mental States</brief_title>
  <acronym>NAYAB</acronym>
  <official_title>A Randomised Double Blind Placebo Controlled Pilot Study of Minocycline and/or Omega-3 Fatty Acids Added to Treatment as Usual for At Risk Mental States</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pakistan Institute of Living and Learning</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pakistan Institute of Living and Learning</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized double-blind placebo controlled trial which aims to evaluate the
      efficacy and tolerability of minocycline and Omega-3 fatty acids for patients with ARMS.
      Specifically to determine whether the addition of minocycline and / or Omega-3 fatty acids to
      Treatment as Usual in an operationalized ARMS population in Pakistan:
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary hypothesis is that the persons with ARMS who are prescribed minocycline and / or
      Omega-3 fatty acids will have reduced transition rates to psychosis over a one year follow up
      period (from baseline) compared with Treatment-As-Usual (TAU). The transition rates will be
      lowest in the group receiving minocycline and Omega-3 fatty acids in combination.

      Secondary objective is to determine that the Persons with ARMS who are prescribed minocycline
      and / or Omega-3fatty acids in combination will have greatest symptom reduction compared with
      TAU.

      This study will be a six-month intervention of minocycline and/or Omega-3 fatty acids added
      to TAU in patients with ARMS, using a randomised, placebo-controlled, double-blind factorial
      design.The study will be a four-arm trial: one arm will receive minocycline with TAU; the
      second arm will receive Omega-3 fatty acids with TAU; the third arm will receive both
      minocycline and Omega-3 fatty acids with TAU; the fourth arm will receive placebo with TAU.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Transition to psychotic disorder</measure>
    <time_frame>12 Months</time_frame>
    <description>Structure Clinical interview for DSM-IV(SCID) (Michael B et al,. 2002) to confirm the transition to psychosis.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measured severity ofAt Risk of Mental State ( ARMS) symptoms</measure>
    <time_frame>12 Months</time_frame>
    <description>Comprehensive Assessment of At-Risk Mental States (CAARMS) (Berger, GEet al2006).A semi-structured interview that assists in the identification of individuals at risk of developing a first-episode psychotic disorder and measured the severity of ARMS symptoms.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">320</enrollment>
  <condition>At Risk Mental State (ARMS)</condition>
  <condition>Psychosis</condition>
  <arm_group>
    <arm_group_label>Minocycline</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Minocycline added to TAU Minocycline will be administered in 200mg once daily dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Omega-3 fatty acids</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Omega-3 fatty acids added to TAU Omega-3 fatty acids will be administered in 1.2mg once daily dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Placebo added to TAU</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Minocycline Plus Omega-3 fatty acids</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Minocycline+Omega-3 fatty acids added to TAU ,Minocyline will be administered in 200mg once daily dose and Omega-3 fatty acids 1.2 g taken as once daily dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Minocycline</intervention_name>
    <description>Minocycline added to TAU Minocycline will be administered in 200mg once daily dose</description>
    <arm_group_label>Minocycline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omega-3 fatty acids</intervention_name>
    <description>Omega-3 fatty acids added to TAU Omega-3 fatty acids will be administered in 1.2g once daily dose</description>
    <arm_group_label>Omega-3 fatty acids</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo added to TAU</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Minocycline Plus Omega-3 fatty acids</intervention_name>
    <description>Minocycline will be administered in 200mg once daily dose and Omega-3 fatty acid 1.2g taken as once daily dose</description>
    <arm_group_label>Minocycline Plus Omega-3 fatty acids</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male and female help seeking individuals aged between 16-35 years.

          2. Meets at least one of the criteria for ARMS (see CAARMS Operationalized Intake
             Criteria section below).

          3. Assessed as competent to provide informed consent.

        Exclusion Criteria:

          1. History ofpreviously experiencing a psychotic illness (treated or untreated).

          2. IQ &lt; 70 and/or history of learning disability.

          3. Any pre-existing inflammatory conditions e.g. rheumatoid arthritis.

          4. Organic brain disease e.g. epilepsy.

          5. treatment with an antipsychotic or mood-stabilising agent.

          6. Prior history of intolerance or serious side effects (hepatotoxicity,
             photosensitivity, blood dyscrasias) to any of the tetracyclines or Omega-3 fatty
             acids.

          7. Concomitant penicillin therapy or concomitant anticoagulant therapy.

          8. Active substance abuse (except nicotine or caffeine) or dependence within the last
             three months, according to DSM-V criteria.

          9. Treatment with warfarin or lamotrigine.

         10. Current or previous treatment with tetracycline antibiotics or Omega-3 fatty acids in
             the preceding three months before study entry.

         11. Current treatment with any anti-inflammatory medication.

         12. Treatment with electroconvulsive therapy within the 12 weeks preceding the study.

         13. Active expression of suicidal ideation (CAARMS item 7.3 severity score 6) or current
             aggression/dangerous behaviour (CAARMS item 5.4 severity score 6). 14. Relevant
             current or past hematologic, hepatic, renal, neurological or other medical disorder
             that in the opinion of the principal investigator may interfere with the study.

        15. Pregnant or breastfeeding females.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr.Inti Qurashi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Manchester University ,UK</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dr.Inti Qurashi, MD</last_name>
    <email>Inti.Qurashi@merseycare.nhs.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Prof.Imran B Chaudhry, MD</last_name>
    <email>ibchaudhry@btinternet.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Abasi Shaheed Hospital</name>
      <address>
        <city>Karachi</city>
        <state>Sindh</state>
        <zip>72000</zip>
        <country>Pakistan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Prof Munir Hamarani, FCPS</last_name>
      <phone>00923009272002</phone>
      <email>mmham@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Prof Munir Hamarani, FCPS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Civil hospital Karachi</name>
      <address>
        <city>Karachi</city>
        <state>Sindh</state>
        <zip>72000</zip>
        <country>Pakistan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Prof Raza U Rahman, FCPS</last_name>
      <phone>00-92-21-9215740-50</phone>
      <phone_ext>2500</phone_ext>
      <email>razaur@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Prof Raza U Rahman, FCPS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Karwn e Hayat</name>
      <address>
        <city>Karachi</city>
        <state>Sindh</state>
        <zip>72000</zip>
        <country>Pakistan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr Ajmal Kazmi, MRCPsych</last_name>
      <phone>00923213783890</phone>
      <email>kazmiajmal@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Dr Ajmal Kazmi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Colleges and Universities</name>
      <address>
        <city>Karachi</city>
        <state>Sindh</state>
        <country>Pakistan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Community</name>
      <address>
        <city>Karachi</city>
        <state>Sindh</state>
        <country>Pakistan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>General Practitioners (GPs)</name>
      <address>
        <city>Karachi</city>
        <state>Sindh</state>
        <country>Pakistan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr.Jawahar Lal, FCPS</last_name>
      <phone>00923333856799</phone>
      <email>dr.jawahar81@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institute of Behavioral Sciences</name>
      <address>
        <city>Karachi</city>
        <state>Sindh</state>
        <country>Pakistan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shehla Ahmed</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Pakistan</country>
  </location_countries>
  <link>
    <url>http://pill.org.pk</url>
    <description>Website of Pakistan Institute of Learning and Living</description>
  </link>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 3, 2015</study_first_submitted>
  <study_first_submitted_qc>October 3, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 6, 2015</study_first_posted>
  <last_update_submitted>February 3, 2018</last_update_submitted>
  <last_update_submitted_qc>February 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>At Risk of Mental State</keyword>
  <keyword>Prodromal Phase</keyword>
  <keyword>Psychosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psychotic Disorders</mesh_term>
    <mesh_term>Mental Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Minocycline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

